Dr. Anthony Mato, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
12 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
TP53 positive
Cys481 resistance mutation negative
BCL2 negative
2T-Lymphoblastic Leukemia/Lymphoma
TP53 positive
Cys481 resistance mutation negative
BCL2 negative
Affiliated Hospitals
Clinical Trials Anthony Mato, MD is currently running
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Triple Combo Therapy
for Chronic Lymphocytic Leukemia
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Recruiting1 award Phase 216 criteria
More about Anthony Mato, MD
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Anthony Mato, MD has experience with
- Venetoclax
- Obinutuzumab
- Zanubrutinib
- Pirtobrutinib
- Rituximab
- Observation
Breakdown of trials Anthony Mato, MD has run
Lymphoma
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony Mato, MD specialize in?
Anthony Mato, MD focuses on Lymphoma and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Lymphoma has involved TP53 positive patients, or patients who are Cys481 resistance mutation negative.
Is Anthony Mato, MD currently recruiting for clinical trials?
Yes, Anthony Mato, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Anthony Mato, MD has studied deeply?
Yes, Anthony Mato, MD has studied treatments such as Venetoclax, Obinutuzumab, Zanubrutinib.
What is the best way to schedule an appointment with Anthony Mato, MD?
Apply for one of the trials that Anthony Mato, MD is conducting.
What is the office address of Anthony Mato, MD?
The office of Anthony Mato, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.